This study has three parts called screening, treatment, and follow up. During screening, doctors will do tests to see if a person can join the study. If eligible, participants will be placed into one of two groups by chance. One group will take a medicine called rocbrutinib, and the other group will take a medicine called pirtobrutinib. Both medicines are taken by mouth once each day. During the study, participants will have regular clinic visits, blood tests, and scans to check their health and see how the cancer is responding. They can continue taking the study medicine as long as it is helping and side effects are manageable. After treatment ends, doctors will continue to check on participants for several years through follow up visits and phone calls.